The polymerase chain reaction (PCR) has been a cornerstone of molecular biology for decades. But in recent years, the digital PCR (dPCR) variant has emerged as a powerful, high-precision technology — offering absolute quantification of nucleic acids, higher sensitivity for rare targets, and strong utility in research, diagnostics, liquid biopsy, gene therapy monitoring, and more. In parallel, market demand for dPCR is rising sharply, driven by growing emphasis on precision medicine, genomic diagnostics, and biomarker quantification.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
Market Size & Growth Drivers
The global digital PCR market was valued at about USD 6.83 billion in 2023 and is projected to grow to around USD 15.86 billion by 2031, representing a compound annual growth rate (CAGR) of approximately 11.1%.
Key growth drivers include:
-
Increasing adoption of precision/personalised medicine and need for high-sensitivity molecular assays.
-
Rising demand for absolute quantification of nucleic acids (e.g., minimal residual disease in cancer, liquid biopsy, infectious disease monitoring).
-
Technological innovations in dPCR (multiplexing, automation, software/analytics) making it more accessible and efficient.
Top Companies in the dPCR Market
Below are some of the key established players in the dPCR space, along with their major contributions and strengths.
1. Bio‑Rad Laboratories, Inc. (US)
Bio-Rad is widely cited as a leader in dPCR, especially via its “droplet digital PCR (ddPCR)” technology platform.
-
Offers instruments like the QX200 Droplet Digital PCR System among others.
-
Strong presence in research and clinical labs; large installed base in Europe for example.
-
Focus on reagents, hardware, software and application support.
2. Thermo Fisher Scientific, Inc. (US)
Thermo Fisher is another major player in the dPCR market with a broad footprint in instruments, reagents and molecular diagnostics.
-
Launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System (for example) that supports high throughput and accuracy.
-
Strong global presence and capability across research/clinical markets.
3. QIAGEN N.V. (Germany/Netherlands)
QIAGEN provides digital PCR platforms and associated reagents, particularly aimed at diagnostics and translational research.
-
Offers the QIAcuity Digital PCR System – designed for high throughput and clinically relevant workflows.
-
Strategic partnerships and acquisitions strengthening its molecular diagnostic positioning.
4. F. Hoffmann‑La Roche Ltd. (Switzerland)
Roche is a major diagnostics giant, now active in the dPCR space.
-
In August 2022 launched its Digital LightCycler® System — Roche’s first digital PCR system for highly sensitive DNA/RNA quantification.
-
Positioned in oncology, genetic disease, infectious disease markets with emphasis on rare mutation detection.
5. Other Notable Players
-
Agilent Technologies, Inc., Merck KGaA (Life Sciences division), Fluidigm Corporation, Stilla Technologies (France) and others are also active and moving up on innovation curves.
-
For instance, Stilla Technologies has developed a six-colour digital PCR instrument (see below).
Emerging Technologies and Innovations in dPCR
The next wave of innovation is making digital PCR even more powerful, versatile, and clinically relevant. Key themes to watch:
Multiplexing and High-Colour Detection
Traditional dPCR often used one or two colours/fluorophores. Recent systems support 4-6 colours enabling many targets (mutations, genes) to be quantified in one reaction.
For example: Stilla Technologies launched the world’s first six-colour digital PCR instrument (Naica™ System Prism) enabling complex multiplex panels (e.g., for oncology, infectious diseases).
Integration with AI, Data Analytics and Cloud
With greater data per assay (droplet counts, fluorescence amplitudes, partitions etc) software/analytics are gaining importance.
Emerging capabilities include AI-driven data interpretation, automated droplet classification, anomaly detection, rare event quantification.
One academic paper (SAM-dPCR) shows a zero-shot segmentation AI model enabling real-time high-throughput quantification of microreactors.
UltraRare Target Detection & Liquid Biopsy
Because dPCR offers absolute quantification and higher sensitivity than qPCR, it’s ideal for detecting very low levels of circulating tumour DNA (ctDNA), minimal residual disease (MRD), rare pathogens or low-abundance transcripts. This is driving adoption in oncology, transplant monitoring, infectious disease.
Improved Workflow, Automation & Accessibility
Automation of droplet generation, reading, data analysis, end-to-end workflows reduces labor/time and improves reproducibility. Platforms are increasingly user-friendly and compatible with clinical labs.
For instance, Roche’s Digital LightCycler System is designed for trace DNA/RNA quantification in clinical labs.
Broader Application Footprint
dPCR is being extended beyond research into diagnostics (clinical use), forensics, food testing, environmental monitoring and gene therapy/viral vector quantification. This expansion into new verticals fuels market growth.
Why These Technologies Matter
-
Precision medicine & diagnostics: More accurate quantification of mutations, viral loads, gene transcripts enables better treatment decisions.
-
Lower limit of detection: dPCR’s ability to detect very low copy numbers of nucleic acid targets expands possibilities in early detection, monitoring of disease relapse, and screening.
-
Multiplex capability: Being able to monitor multiple targets in one assay reduces cost/time and increases throughput.
-
Clinical transition: As dPCR moves from research to clinical diagnostics, labs require robust, automated, validated workflows—this trend is increasing.
-
New market segments: Gene therapy manufacturing, viral vector quantification, liquid biopsy, environmental/food testing—these are all growth arenas for dPCR technologies.
Challenges & Considerations
Despite strong momentum, there are still hurdles:
-
Cost: Instruments, consumables and workflow cost remain higher than standard qPCR in many settings.
-
Clinical validation & regulatory clearance: Use in diagnostics requires stringent validation and regulatory approval (FDA/CE etc).
-
Competition from other technologies: For some applications, next-generation sequencing (NGS) or other high throughput platforms may compete with dPCR.
-
Standardization & data interpretation: While dPCR gives absolute counts, interpreting results (especially multiplex panels, rare targets) requires experienced analysts and robust software/algorithms.
-
Throughput vs cost trade-off: For very high throughput, dPCR may need to scale competitively (time, cost) compared to alternatives.
Outlook: What to Watch
Looking ahead, the following areas will likely shape how the dPCR market evolves:
-
Further integration of AI/ML and cloud analytics to simplify data handling, improve accuracy and automate decision support.
-
Higher multiplexing capability (more colours/targets per assay) enabling comprehensive panels (oncology, gene therapy, infectious diseases).
-
More clinical diagnostic adoption — as platforms gain regulatory clearance and become clinical-lab ready, adoption will expand.
-
Lower cost and increased accessibility — smaller footprint, simpler workflows, cheaper consumables will enable broader use in smaller labs and resource-limited settings.
-
Expansion into new “markets” — e.g., gene therapy vector quantification, liquid biopsy monitoring, environmental/food diagnostics, cell & gene therapy manufacturing QC.
-
Partnerships & service models — as seen in collaborations (e.g., Bio-Rad & Oncocyte for transplant monitoring assay) enabling specialized assays built on dPCR platforms.
Conclusion
The digital PCR market is entering a phase of strong growth and innovation. With major players like Bio-Rad, Thermo Fisher, QIAGEN and Roche driving development, and emerging innovators like Stilla Technologies pushing multiplexing and automation forward, dPCR is becoming more capable, more clinically relevant, and more accessible.
For companies operating in genomics, diagnostics, biotech and research, staying aware of the evolving dPCR landscape is critical — both from the instrument/reagent side and the data/analysis side. As the technology matures and adoption broadens, dPCR is poised to play a central role in precision medicine, liquid biopsy, gene therapy monitoring and many other next-generation molecular applications.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204